Today Stories

Bracknell, UK. 29th January 2023: PharmiWeb, the leading global life science news and jobs portal, is excited to unveil its new branding in line with the company’s 25th anniversary celebrations. This fresh visual identity symbolises PharmiWeb’s commitment to continuous evolution, and to creating a standout user experience for both candidates and clients, whilst still paying homage to the company’s origins. Whilst the new branding maintains the trusted blue, grey, and golden yellow colour palette that has become synonymous with PharmiWeb, new photo-based imagery has been utilised on the PharmiWeb websites to inject new life into the brand. A new ‘dot’ design has also been used to bring dynamism and vibrancy into the brand. The PharmiWeb logo remains the same, with a tagline that has been re…

If approved, AstraZeneca and Daiichi Sankyo’s Enhertu will potentially be the firstHER2-directed treatment and antibody drug conjugate to receive a tumour-agnostic indication Application based on results from DESTINY-PanTumor02 trial and supported by additional Enhertu data Submission to be reviewed under FDA Real-Time Oncology Review and Project Orbis AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (immunohistochemistry [IHC] 3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options. The sBLA is based on data from the ongoi…

– US$223 million expansion will add biologics capacity to AbbVie manufacturing network– Singapore manufacturing site to grow to more than 500 employees following expansion– Construction will commence immediately with facilities becoming operational in 2026 SINGAPORE Jan. 26, 2024 – AbbVie (NYSE: ABBV) strengthened its manufacturing capabilities by breaking ground Thursday on a new US$223 million (S$301 million) expansion of its Singapore manufacturing facility. This new investment will add more than 100 jobs and new biologics manufacturing capacity to AbbVie's global network. Located in Singapore's Tuas Biomedical Park, AbbVie's Singapore plant is a state-of-the-art small-molecule and biologics manufacturing facility serving markets worldwide. This new investment will add 24,000 liters of…

Dublin, Ireland – 24 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced results from a recent industry survey of over 100 professionals engaged in obesity-related clinical research to measure industry opinions on trends within this therapeutic area. The majority of respondents believe the future of obesity therapies lies in trials that are designed to measure more than one outcome. There is much overlap between obesity and co-morbidities such as diabetes, steatosis (fatty liver), and cardiovascular disease, and in line with this, most respondents (64%) felt combination therapies would be the primary focus of future research. Furthermore, half of respondents are employing multi-indication studies…

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on the NASDAQ Global Select Market and Mirati is now a wholly owned subsidiary of Bristol Myers Squibb. “The closing of the Mirati transaction is a significant milestone in our efforts to further diversify our oncology portfolio and strengthen our pipeline in the latter half of the decade and beyond,” said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. “Mirati’s incredibly talented employees have built a strong portfolio of assets and capabilities that are highly complementary with BMS’. We welcome them and look forward t…

Sano Genetics is the only software platform tailored to running precision medicine clinical trials, leveraging AI to manage all aspects from design to patient recruitment, to genetic and other biomarker testing and patient engagement Precision medicine is a fast-growing category - today more than 30% of trials are precision-driven which is predicted to reach 80% by the end of the decade Sano Genetics is experiencing huge demand for its product, experiencing 5x growth ARR year-on-year and now serving four of the major pharmaceutical companies  New funding brings the total raised by the company to $22M to help it meet demand and further automate its processes  Cambridge, UK, 22nd January 2024: Sano Genetics, a software company accelerating precision medicine research, has raised $11.4 mill…

GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients. WALTHAM, Mass. & MONZA, Italy--(BUSINESS WIRE)-- Thermo Fisher Scientific, the world leader in serving science, has received Good Manufacturing Practice (GMP) approval from the Italian Medicines Agency (AIFA) allowing the company to manufacture RNA-based products at its Monza, Italy site. The approval and associated certification support increased accessibility to novel therapies for patients with difficult to treat conditions, marking a significant achievement within the Thermo Fisher Scientific network and for Italy as a whole. “RNA technology is being explored for a variety of modalities, including rare diseases and cancer which have limited treatment options,”…

Specialist preclinical contract research organisation (CRO) Cellomatics Biosciences has heralded the start of its next successful phase with four promotions and eight new arrivals. Dr Shailendra Singh, CEO of Cellomatics Biosciences, comments: “Capitalising on our existing strengths and internal team expertise, we intend to further consolidate our position as a specialist biology CRO by broadening and deepening our service offerings in 2024. With these new appointments and internal restructuring, we are poised to catapult ourselves to the next phase of our growth journey.” Cellomatics is building on its expanding client base which now boasts over a hundred global clients, delivering approximately 320 scientific projects across all therapeutic areas of which sixty-six projects were complete…

High scores in development and steering practices reflect how individual growth contributes to our company purpose Benefits focusing on employee wellbeing continue to stand out The Top Employers Institute awarded Boehringer Ingelheim for the fourth year in a row a “Global Top Employer”, one of 17 globally certified companies. The 2024 certification reflects the impact of the comprehensive learning and development opportunities at Boehringer. Boehringer’s employer offerings receive particularly high scores in the categories “Develop” and “Steer” pointing out a link between individual development and the company purpose of transforming lives for generations. The internal Boehringer Ingelheim University is a key element in this. It includes a state-of-the-art virtual campus where learni…

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment - BOSTON--(BUSINESS WIRE)--Jan. 16, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “On the heels of the historic FDA approval of CASGEVY for sickle cell disease, it is exciting to now secure approval for TDT well ahead of the PDUFA date,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “TDT patients deserve new, potentially curative treatment options, and we look forward to bri…

Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5 Tecentriq SC reduces treatment time by approximately 80%, compared with standard IV infusion6 Roche is working closely with national health systems in Europe to ensure patients can access Tecentriq SC as quickly as possible Basel, 16 January 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladde…

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. With an investment of EUR 120 million, the company will increase the manufacturing capacity of new and existing medications, some of them in the late-stage development of the company’s strong innovation pipeline. Main disease areas include cardio-renal-metabolic (CRM) diseases, mental health, and pulmonary fibrosis. The expansion will create 110 additional jobs and boost medicine exports from Greece, particularly of Jardiance®, a medication used to treat type 2 diabetes, chronic (long-term) heart failure and chronic kidney disease, to the US market. Greek Prime Minister Kyriakos Mitsotakis attended the groundbreaking ceremony at the K…

Ingelheim, Germany — 9 January 2024 — Boehringer Ingelheim has kicked off 2024 on a high note by announcing that the company is entering five new R&D partnerships to further enable and accelerate the company’s commitment to transform the lives of patients world-wide. Through these strategic partnerships, Boehringer is building on past years successes, including 2023 where the company entered into more than 100 new R&D partnerships.  The five partnerships just unveiled focus on addressing high unmet patient needs across three leading of Boehringer’s focus areas: Oncology, cardio-renal-metabolic and fibro-inflammatory diseases: The collaboration with Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) will focus on the development of new mRNAi therapeutics f…

Bracknell, UK. 9th January 2024: PharmiWeb, the leading global life science news and jobs portal, is excited to announce it will be celebrating its 25th anniversary this month. To commemorate this significant milestone, PharmiWeb will be running a month-long celebration campaign throughout January, recognising the company’s achievements over the past 25 years, and expressing gratitude to the loyal clients and candidates who have played a crucial role in its success. Since its inception in 1999, PharmiWeb has been connecting life science professionals with the latest news, jobs, and events from across the industry, whilst helping life science recruiters locate the top talent they need to drive innovation. After launching as a job board, PharmiWeb has evolved into an industry-leading platfor…

Survey points to importance of strategic engagement with investors and effective asset development strategies to optimise funding Dublin, Ireland – 8 January 2024 – ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the current state of play for biotech companies and the research and development (R&D) strategies they can adopt to attract and best utilise investment funding. A recent survey of over 130 biotech executives, published by ICON, shows that 60% of respondents expected to increase R&D spending, whilst only 2% planned to reduce funding. While respondents were confident in their outlook with regards to investment milestones and product su…

Most comprehensive and ethnically diverse genomic coverage on a high throughput microarray delivers multi-disease and pharmacogenomic research analysis across global populations CARLSBAD, Calif.--(BUSINESS WIRE)-- Earlier this year, scientists unveiled the first draft of the pangenome, based on full genetic blueprints from 47 people around the world to create a more diverse representation of the human genome1. To more accurately account for this richer picture of human genomic variation, Thermo Fisher Scientific has launched the new Axiom™ PangenomiX Array*, its largest and most ethnically diverse array to date, offering optimal genetic coverage for population scale disease studies and pharmacogenomic research. This press release features multimedia. View the full release here: https://www…

INDIANAPOLIS, Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services. "A complex U.S. healthcare system adds to the burdens patients face when managing a chronic disease. With LillyDirect, our goal is to relieve some of those burdens by simplifying the patient experience to help improve outcomes," said David A. Ricks, Lilly's chair and CEO. "LillyDirect offers more choices in how and where people access healthcare, including a conv…

Calibre Scientific has acquired LineaLAB, SL, a distributor of analytical, bio and laboratory equipment based in Badalona (Barcelona), Spain. LineaLAB is Calibre Scientific’s fourth acquisition in Spain and further bolsters its presence in the Iberian Peninsula. 50.9% of the shares in LineaLAB, SL were sold by the family of the company's late founder and former managing director, Sebastián Estrades. Brand Group has sold its 49.1% stake in LineaLAB. Divestment serves to focus on Brand Group's core businesses. BARCELONA, Spain and FRANKFURT AM MAIN, Germany and LOS ANGELES, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific has acquired LineaLAB, SL, a provider of analytical, bio and laboratory equipment based in Badalona (Barcelona). LineaLAB is Calibre Scientific’s fourth acquisition i…

Ingelheim, Germany, Mölndal, Sweden and Kunshan, China — 3 January 2024 — Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of small interfering RNA (siRNA) therapeutics with Boehringer’s commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases (CRM). More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver. Over time, NASH causes scar tissue formation, which in…

Agreement Expands Access to Labcorp's Diagnostics Capabilities and Services BURLINGTON, N.C., Nov. 20, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the completion of the previously announced transaction with Legacy Health to acquire select assets of Legacy's outreach laboratory business. Labcorp also now manages Legacy's inpatient hospital laboratories through a long-term agreement to provide staffing, leadership, scientific knowledge, analytics, supply chain services and laboratory support.  "This milestone will benefit communities in Oregon and Southwest Washington by expanding access to Labcorp's industry-leading laboratory services and diagnostic testing," said Rajat Mehta, Senior Vice President of Labcorp…